Effectiveness of carvedilol alone versus carvedilol + pimobendan for severe congestive heart failure. For the Keio Interhospital Cardiology Study (KICS) Group.
Yoshikawa
T
T
Cardiology Division, Department of Medicine, Keio University School of Medicine, Tokyo, Japan. tyoshi@mc.med.keio.ac.jp
Baba
A
A
Suzuki
M
M
Yokozuka
H
H
Okada
Y
Y
Nagami
K
K
Takahashi
T
T
Mitamura
H
H
Ogawa
S
S
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D002227:Carbazoles / Q000494:pharmacology / Q000627:therapeutic use*; D002316:Cardiotonic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000077261:Carvedilol; D004359:Drug Therapy, Combination; D005260:Female; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D011412:Propanolamines / Q000494:pharmacology / Q000627:therapeutic use*; D011724:Pyridazines / Q000494:pharmacology / Q000627:therapeutic use*; D016277:Ventricular Function, Left / Q000187:drug effects
D000319:Adrenergic beta-Antagonists; D002227:Carbazoles; D002316:Cardiotonic Agents; D011412:Propanolamines; D011724:Pyridazines; D000077261:Carvedilol; C041648:pimobendan